Psychopharmacology Practice Questions

Q: Which of the following is the first-line pharmacological treatment for obsessive-compulsive disorder?

Selective Serotonin Reuptake Inhibitors. ***Selective Serotonin Reuptake Inhibitors*** - **SSRIs** are widely recognized as the **first-line pharmacological treatment** for OCD due to their efficacy in reducing obsessive thoughts and compulsive behaviors. - They work by increasing the **serotonin levels** in the brain, thereby improving mood and reducing anxiety. *Beta blockers* - **Beta blockers** are primarily used to treat **physical symptoms of anxiety**, such as palpitations and tremors, but do not directly address the core symptoms of OCD. - They are not considered a first-line treatment for psychiatric conditions beyond performance anxiety or specific phobias. *Antipsychotics* - **Antipsychotics** may be used as an **adjunctive treatment** in refractory cases of OCD, particularly when there is a co-occurring psychotic disorder or severe tics. - They are not a first-line therapy because their primary mechanism of action targets dopamine, which is not the main pathway implicated in OCD. *Tricyclic antidepressants* - While some **TCAs**, particularly **clomipramine**, have shown efficacy in treating OCD, they are generally considered **second-line treatments** due to their less favorable side effect profile compared to SSRIs. - Their use is limited by potential side effects such as **anticholinergic effects**, cardiovascular risks, and a higher risk of overdose.

Q: A patient with a history of major depressive disorder is treated with an SSRI and presents with restlessness, hyperreflexia, and myoclonus. What is the likely diagnosis?

Serotonin syndrome. ***Serotonin syndrome*** - The constellation of **restlessness**, **hyperreflexia**, and **myoclonus** in a patient taking an **SSRI** is highly characteristic of **serotonin syndrome**, reflecting excessive serotonin activity. - This syndrome often involves a triad of mental status changes, autonomic hyperactivity, and neuromuscular abnormalities. *Neuroleptic malignant syndrome* - Characterized by **severe muscle rigidity**, **fever**, **autonomic dysfunction**, and altered mental status, often associated with antipsychotic use. - Though it involves autonomic and neuromuscular symptoms, the presenting symptoms of hyperreflexia and myoclonus are more indicative of serotonin syndrome rather than the rigidity seen in NMS. *Anticholinergic toxicity* - Presents with symptoms like **mydriasis**, **dry mouth**, **tachycardia**, **urinary retention**, and altered mental status due to blocking acetylcholine receptors. - The patient's symptoms of hyperreflexia and myoclonus are not typical for anticholinergic toxicity. *Alcohol withdrawal* - Symptoms range from tremors and anxiety to seizures and delirium tremens, occurring after reducing or stopping chronic alcohol intake. - While it can involve agitation, the specific combination of restlessness, hyperreflexia, and myoclonus in a patient on an SSRI points away from alcohol withdrawal as the primary diagnosis.

Q: A 30-year-old male with a history of PTSD presents with nightmares and hypervigilance. What is the most appropriate first-line pharmacological treatment?

SSRIs. ***SSRIs*** - **Selective Serotonin Reuptake Inhibitors (SSRIs)** are considered the **first-line pharmacological treatment** for PTSD due to their efficacy in reducing core symptoms like nightmares, hypervigilance, and intrusive thoughts. - They work by increasing serotonin levels in the brain, which helps to regulate mood, anxiety, and sleep, thereby alleviating PTSD symptoms. *Benzodiazepines* - While they can provide **short-term relief** for acute anxiety and sleep disturbances, benzodiazepines are generally **not recommended as first-line** or long-term treatment for PTSD due to risks of dependence, tolerance, and potential for worsening PTSD symptoms over time. - They do not address the underlying pathology of PTSD and can interfere with the effectiveness of psychotherapy. *Antipsychotics* - **Antipsychotics** are typically used for conditions involving psychosis, severe mood dysregulation, or as an **adjunct treatment** for PTSD when other medications have been insufficient. - They are **not considered a first-line monotherapy** for the core symptoms of PTSD due to their potential side effects and limited evidence for primary efficacy. *Beta-blockers* - **Beta-blockers**, such as propranolol, can help manage some physiological symptoms of anxiety in PTSD, like **tachycardia** and **tremors**. - However, they do not effectively address the cognitive and emotional symptoms of PTSD, such as nightmares, intrusive thoughts, or hypervigilance, and are not considered a first-line treatment.

Q: A 45-year-old woman with schizophrenia presents with persistent delusions and hallucinations despite adequate trials of risperidone and olanzapine at therapeutic doses. What is the most appropriate next step?

Switch to clozapine. ***Switch to clozapine*** - **Clozapine** is an **atypical antipsychotic** indicated for **treatment-resistant schizophrenia**, defined as inadequate response to two different antipsychotics (one of which should be a second-generation antipsychotic) taken at adequate doses and duration. - Given the patient's persistent delusions and hallucinations despite adherence to risperidone, clozapine is the most appropriate next step for better symptom control. *Increase the risperidone dose* - While dose escalation is often an initial strategy, continued symptoms despite adherence to an existing antipsychotic suggest that the patient may be experiencing **treatment-resistant schizophrenia**, and merely increasing the dose may not be sufficient. - Moving to a medication with a different mechanism or higher efficacy in such cases, like **clozapine**, is typically more effective than simply increasing the dose of a drug that has already failed. *Add a benzodiazepine* - **Benzodiazepines** are generally used for acute agitation or anxiety in schizophrenia, but they do not address the **primary psychotic symptoms** like delusions and hallucinations. - Adding a benzodiazepine would *not* treat the underlying psychosis and carries risks of dependence and sedation. *Start cognitive-behavioral therapy* - **Cognitive-behavioral therapy (CBT)** can be a helpful adjunct for managing symptoms, reducing distress, and improving functioning in schizophrenia. - However, it is not a primary treatment for actively psychotic symptoms and would not be the first-line intervention when pharmacological treatment has failed to control delusions and hallucinations.

Q: A 28-year-old male with schizophrenia is prescribed clozapine. What is the most important laboratory test to monitor regularly?

White blood cell count. ***White blood cell count*** - **Clozapine** carries a significant risk of **agranulocytosis**, a severe reduction in **white blood cell count (neutrophils)**, making regular monitoring crucial. - Due to this life-threatening adverse effect, a **baseline WBC count** and **absolute neutrophil count (ANC)** must be established before treatment, and then monitored **weekly for the first six months**, then bi-weekly, and eventually monthly, according to established protocols. *Liver function tests* - While liver enzyme elevations can occur with clozapine, they are generally less frequent and less severe than the risk of agranulocytosis. - Routine **liver function tests (LFTs)** are typically monitored, but not with the same urgency or strictness as WBC counts. *Renal function tests* - **Clozapine** is primarily metabolized by the liver, and significant renal impairment is not a primary concern for closely monitoring during treatment initiation. - While general renal health is important, **renal function tests (RFTs)** are not part of the mandatory, life-saving monitoring protocol for clozapine. *Lipid profile* - **Clozapine** can cause metabolic side effects, including **weight gain**, **dyslipidemia**, and **glucose dysregulation**, which necessitate monitoring of the **lipid profile** and **blood glucose levels**. - However, these metabolic effects, while important for long-term health, are not as acutely life-threatening as agranulocytosis, making WBC count the most immediate and critical laboratory test.

Q: Which of the following is the drug of choice for managing acute mania in bipolar disorder?

Lithium. ***Lithium*** - **Lithium** has historically been considered the **gold standard** and **classical first-line treatment** for acute mania in bipolar disorder, with well-established efficacy in mood stabilization. - It works by modulating **neurotransmitter systems** and **intracellular signaling pathways** (including inhibition of inositol monophosphatase) to reduce manic symptoms. - **Note:** Current guidelines (APA, CANMAT) recognize **multiple first-line options** including lithium, valproate, and antipsychotics, though lithium remains the **prototype mood stabilizer** taught in medical education. - Onset of antimanic effect: **7-14 days**. *Valproate* - **Valproate** (sodium valproate/divalproex) is equally effective for acute mania and is also considered a **first-line agent** in current clinical practice, particularly for **mixed episodes** and **rapid cycling**. - Its mechanism involves increasing **GABA activity** and stabilizing neuronal membranes. - **Faster onset of action** than lithium (within days), making it advantageous in acute settings. - Often preferred when rapid control is needed or in patients with contraindications to lithium. *Carbamazepine* - **Carbamazepine** is an anticonvulsant used as a **mood stabilizer**, particularly for patients who do not respond to lithium or valproate. - It acts by blocking **voltage-gated sodium channels** and enhancing GABAergic transmission. - Considered a **second-line** or **alternative agent** for acute mania due to enzyme induction and drug interactions. *Lamotrigine* - **Lamotrigine** is primarily effective in preventing **depressive episodes** in bipolar disorder and has **minimal to no efficacy** for acute mania. - It works by blocking **voltage-sensitive sodium channels** and inhibiting the release of excitatory neurotransmitters like glutamate. - May even worsen mania or precipitate mixed states; **not indicated** for acute mania treatment.

Q: Which selective serotonin reuptake inhibitor (SSRI) is frequently prescribed as the first-line treatment for depression?

Fluoxetine. ***Fluoxetine*** - **Fluoxetine** is one of the most widely prescribed **first-line SSRIs** for depression and is frequently chosen in clinical practice. - Its **long half-life (4-6 days for active metabolite norfluoxetine)** reduces risk of discontinuation syndrome and allows for more flexible dosing. - **Activating properties** can be beneficial for patients with psychomotor retardation or fatigue-predominant depression. - Well-established efficacy across depressive and anxiety disorders with extensive clinical experience. *Amitriptyline* - **Amitriptyline** is a **tricyclic antidepressant (TCA)**, not an SSRI. - TCAs are typically **second-line** or reserved for treatment-resistant depression due to significant **anticholinergic effects** (dry mouth, constipation, urinary retention), **cardiovascular side effects** (orthostatic hypotension, arrhythmias), and **higher toxicity in overdose**. - Narrow therapeutic index makes them less safe than SSRIs. *Paroxetine* - **Paroxetine** is also an SSRI and is used as a first-line agent, though it has some distinctive characteristics. - More **sedating** than other SSRIs due to anticholinergic properties, which can be useful for anxious depression but may cause weight gain. - **Shortest half-life** among SSRIs leads to more severe **discontinuation syndrome** if doses are missed. - While effective, it is often not the preferred first choice due to withdrawal concerns and side effect profile. *Venlafaxine* - **Venlafaxine** is a **serotonin-norepinephrine reuptake inhibitor (SNRI)**, not a selective serotonin reuptake inhibitor. - Generally considered when SSRIs are ineffective or for specific indications like severe depression or generalized anxiety disorder. - Can cause **dose-dependent hypertension** and has a more complex side effect profile compared to SSRIs.

Q: A 45-year-old male with a history of schizophrenia presents with poor adherence to oral medication. What is the most appropriate management?

Switch to a long-acting injectable antipsychotic. ***Switch to a long-acting injectable antipsychotic*** - **Long-acting injectable (LAI) antipsychotics** improve medication adherence by reducing the frequency of administration, which is crucial for patients with a history of poor oral medication adherence. - This approach ensures consistent therapeutic drug levels, reducing the risk of **relapse** and rehospitalization in patients with schizophrenia. *Switch to a different oral antipsychotic* - Switching to another **oral antipsychotic** does not address the fundamental issue of poor adherence, as the patient may still struggle with taking daily pills. - While a different oral medication might offer a better side effect profile or efficacy, it won't resolve the primary problem of **non-adherence**. *Add a benzodiazepine* - **Benzodiazepines** are primarily used for acute agitation, anxiety, or insomnia and are not a long-term treatment for schizophrenia or a solution for antipsychotic non-adherence. - Their use carries risks of **dependence** and sedation, and they do not address the positive or negative symptoms of schizophrenia itself. *Start cognitive-behavioral therapy* - While **cognitive-behavioral therapy (CBT)** can be beneficial for managing symptoms and improving coping skills in schizophrenia, it is not the most immediate or direct solution for poor medication adherence. - Adherence often requires a more tangible intervention to ensure medication is taken, especially in patients with **insight difficulties** or organizational challenges.

Question 1

Which of the following is the first-line pharmacological treatment for obsessive-compulsive disorder?

Accepted Answer

Selective Serotonin Reuptake Inhibitors

Answer

Beta blockers

Answer

Antipsychotics

Answer

Tricyclic antidepressants

Question 2

A 35-year-old male with schizophrenia experiences persistent delusions despite being on antipsychotic medication and does not show significant improvement. What is the most appropriate next step?

Accepted Answer

Switch to clozapine

Answer

Start cognitive-behavioral therapy

Answer

Switch to a long-acting injectable antipsychotic

Answer

Increase the dose of the current antipsychotic

Question 3

A patient with a history of major depressive disorder is treated with an SSRI and presents with restlessness, hyperreflexia, and myoclonus. What is the likely diagnosis?

Accepted Answer

Serotonin syndrome

Answer

Neuroleptic malignant syndrome

Answer

Anticholinergic toxicity

Answer

Alcohol withdrawal

Question 4

A 30-year-old male with a history of PTSD presents with nightmares and hypervigilance. What is the most appropriate first-line pharmacological treatment?

Accepted Answer

SSRIs

Answer

Benzodiazepines

Answer

Antipsychotics

Answer

Beta-blockers

Question 5

A 45-year-old woman with schizophrenia presents with persistent delusions and hallucinations despite adequate trials of risperidone and olanzapine at therapeutic doses. What is the most appropriate next step?

Accepted Answer

Switch to clozapine

Answer

Increase the risperidone dose

Answer

Add a benzodiazepine

Answer

Start cognitive-behavioral therapy

Question 6

A 28-year-old male with schizophrenia is prescribed clozapine. What is the most important laboratory test to monitor regularly?

Accepted Answer

White blood cell count

Answer

Liver function tests

Answer

Renal function tests

Answer

Lipid profile

Question 7

A 60-year-old woman with schizophrenia presents with tardive dyskinesia. What is the most appropriate management?

Accepted Answer

Switch to clozapine

Answer

Discontinue antipsychotic medication

Answer

Add a benzodiazepine

Answer

Increase antipsychotic dose

Question 8

Which of the following is the drug of choice for managing acute mania in bipolar disorder?

Accepted Answer

Lithium

Answer

Valproate

Answer

Carbamazepine

Answer

Lamotrigine

Question 9

Which selective serotonin reuptake inhibitor (SSRI) is frequently prescribed as the first-line treatment for depression?

Accepted Answer

Fluoxetine

Answer

Amitriptyline

Answer

Paroxetine

Answer

Venlafaxine

Question 10

A 45-year-old male with a history of schizophrenia presents with poor adherence to oral medication. What is the most appropriate management?

Accepted Answer

Switch to a long-acting injectable antipsychotic

Answer

Switch to a different oral antipsychotic

Answer

Add a benzodiazepine

Answer

Start cognitive-behavioral therapy

Psychopharmacology — MCQs

Psychopharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?